MZEI news .172 Tuberculosis Breakthrough - New Tec

MZEI news .172 Tuberculosis Breakthrough - New Technology To Greatly Reduce Deadly Disease Risk In Hospitals

2012-06-12 08:35 ET - News Release

AsepticSure, a Highly Promising New Disinfection Technology May Hold the Key to Reducing or Even Eliminating TB from Hospitals and Tuberculosis Laboratories, Worldwide.

SAN FRANCISCO, June 12, 2012 /PRNewswire/ -- Medizone International, Inc. (The Company) (MZEI:OB) (MZEI:QB) announced today that in achieving 100% kill rates with TB in three successive trials, it had achieved another important milestone in its understanding of the antimicrobial limits of its recently launched disinfection technology, AsepticSure™.

Dr. Michael E Shannon, President of Medizone International, stated, "With one third of the world's population currently infected with tuberculosis and a new Extreme Drug Resistant Strain of tuberculosis now sweeping across Asia, central Europe and parts of Africa, we felt compelled to evaluate the efficacy of AsepticSure against this daunting bacteria. With a small increase in treatment time (beyond our standard 90 minute protocol, start to finish) we demonstrated that AsepticSure consistently produces >6 log reductions of Mycobacterium terrae, a well established surrogate organism for Mycobacterium tuberculosis."

Chief Medical Officer for Medizone, Dr. Dick Zoutman added, "Although tuberculosis is not spread through contact with contaminated surfaces; contaminated ventilation systems, isolation wards and tuberculosis laboratories have proven very difficult to disinfect and hence, pose a serious threat to the health and safety of those persons occupying these spaces. Our results indicate that AsepticSure technology can very effectively mitigate that risk